Stay updated on Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial page.

Latest updates to the Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial page
- Check7 days agoChange DetectedThe study record now shows that recruitment is closed to new participants, and the history includes a new revision (v3.6.0) with the prior revision (v3.5.5) removed.SummaryDifference0.3%

- Check14 days agoChange DetectedA new revision entry v3.5.5 was added to the page's history and the previous v3.5.4 entry was removed, updating the page's version history.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedThe page’s revision label was updated from v3.5.3 to v3.5.4, signaling a new release version of the page. This reflects a background update to the site's text and structure without changing the study details.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page revision was updated from v3.5.2 to v3.5.3, indicating a small version update that does not modify study details or user-facing information.SummaryDifference0.1%

- Check64 days agoChange DetectedA new revision entry v3.5.2 was added and the v3.5.0 revision was removed from the record history.SummaryDifference0.1%

- Check93 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

Stay in the know with updates to Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bortezomib vs Carfilzomib in Newly Diagnosed Multiple Myeloma Clinical Trial page.